Cable Viewer

Currently released so far... 12453 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01 2011/05/02 2011/05/03 2011/05/04 2011/05/05

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/06
1986/05
1987/06
1988/01
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/06 1992/12
1993/10
1996/11
1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/09 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/08 2002/09 2002/11
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy Niamey Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples Consulate Naha
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ASEC AORC AMGT APER AU AF AS ACBAQ AFGHANISTAN AFIN AR AE AJ ADANA AEMR AG ATRN ADPM APECO AGAO AMED AX AM AL ADCO AA AECL AADP ABUD AMEX ACAO ANET AODE ASCH AY APEC AID AORG ASEAN AFSI AFSN AINF AGR AROC AO AMBASSADOR AFFAIRS ASIG ABLD ASUP AND ARM ARF AQ ATFN AC ACOA AORL ADM AUC AGMT ACABQ ASEX AFU ALOW AZ APCS AVERY ASECKFRDCVISKIRFPHUMSMIGEG AER AN AIT AMG AGRICULTURE AMCHAMS ACS
BR BA BD BL BO BF BU BILAT BEXP BRUSSELS BK BN BM BT BY BX BTIO BIDEN BG BE BP BBSR BC BTIU BWC BB BH BMGT
CH CY CA CU CS CO CVIS CPAS CMGT CE COUNTER CASC COUNTRY CJAN COUNTERTERRORISM CG CI CD CIDA CJUS CDG CBSA CEUDA CR CM CLMT CAC CBW CODEL COPUOS CWC CIC CW CBE CHR CFED CT CONS CIA CTM CDC CVR CF CLINTON CITEL CLEARANCE COE CN CACS CAN CONDOLEEZZA CB CSW CITT CARSON CNARC CACM CDB CARICOM COM CROS CAPC CTR CV CKGR CBC CL CICTE CIS
DR DHS DA DJ DEA DPRK DEPT DOMESTIC DEAX DOE DS DAO DCM DO DE DK DEFENSE DTRA DISENGAGEMENT DOD
ECON EFIN ELAB ETRD EIND EC EINV EAGR ENRG ETTC EAID EPET ELTN EWWT EAIR EFIS EMIN EG EU ER EUN EPA ENVI EXTERNAL ECPS ENGR ETRC ECIN EN EI ELN ET EINT ETRDEINVTINTCS ES ETRDEINVECINPGOVCS EZ ETRO EDU ETRN EFTA EAIG EK EUREM EURN ECONCS ECONOMICS ENVR ELECTIONS EAP ENIV ECONOMY ESA EINN ECONOMIC EIAR EXBS ECA ECUN EINDETRD EUR EREL EUC ESENV ECONEFIN ECIP ENERG ENNP EFINECONCS EFIM ENGY EAIDS EINVEFIN EINVETC EUMEM ETRA ETC ERNG ETRDECONWTOCS EUNCH ECINECONCS EINVECONSENVCSJA EXIM ERD EEPET
FR FREEDOM FTA FJ FARC FI FTAA FAC FBI FOREIGN FOI FDA FM FAO FAS FINR FOR FINANCE FMLN FO FISO
GM GV GOI GOV GL GAERC GH GT GG GA GY GR GF GCC GE GZ GTIP GERARD GLOBAL GANGS GAZA GTMO
HA HR HUMAN HO HK HU HILLARY HUMOR HI HSTC HURI HYMPSK HEBRON
IR IS IZ IAEA IO IAHRC ID IC IT IRAQI IWC IN IL ISLAMISTS IV ICAO INDO ITPHUM ITPGOV ITALIAN IPR ICRC INTERPOL IQ IBET IMO INR ITRA INTERNAL ICJ ICTY IRS ILO INRA INRO ISRAELI IEA INRB ITALY ITU IBRD IIP ILC INTELSAT IZPREL IMF INMARSAT IRAJ IDA ICTR IA IGAD IF IDP ITF ISRAEL IEFIN IRC IACI
JA JUS JO JP JOSEPH JM JAMES JOHNNIE JOHN
KN KCRM KOMC KNNPMNUC KIPR KPAL KWBG KSCA KFRD KNNP KUNR KTIP KWMN KSTC KFLU KOLY KISL KPAO KMDR KJUS KSTH KDEM KCOR KIRF KAWC KU KTFN KWAC KNPP KERG KSEO KACT KHLS KZ KGHG KTIA KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KCRCM KE KPKO KCIP KDRG KVPR KV KIDE KICC KPRP KBIO KSUM KGIT KCFE KG KBTS KFLO KMPI KS KGIC KPAI KHSA KTLA KSEP KTEX KFSC KOCI KHDP KPLS KTDB KHIV KCSY KSAC KTRD KID KMRS KOM KSAF KRVC KR KMOC KNAR KIRC KBCT KSPR KFIN KBTR KJUST KNEI KAWK KGCC KMCA KREL KMFO KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KFTFN KVRP KCOM KO KLIG KAID KVIR KNSD KHUM KSEC KRAD KPRV KCMR KPWR KCHG KIFR KCFC KICA KPIN KSCI KESS KDEV KTBT KCRS KCGC KOMS KRIM KTER KREC KPOA KWWMN KRGY KPAK KWNM KMIG KDDG KRFD KWMM KWMNCS KX KRCM KPAONZ KNUC KDEMAF KNUP
LY LE LO LG LH LI LTTE LAB LOG LA LT LU LABOR
MARR MOPS MASS MCAP MTCRE MNUC MIL MX MEDIA MO MPOS MU ML MA MP MY MERCOSUR MG MD MW MK MAS MEETINGS MR MT MI MOPPS MASC MTS MLS MILI MAR MTRE MEPN MAPP MTCR MEPI MQADHAFI MAPS MARAD MASSMNUC MEPP MCC MZ MILITARY MDC MRCRE MC MV MIK MUCN
NATO NL NZ NPT NI NAFTA NU NDP NIPP NP NPA NG NRR NO NSC NEW NE NH NR NA NS NSF NZUS NATIONAL NSG NC NT NAR NK NGO NV NSFO NSSP NASA NW NPG NORAD NATOPREL
OTRA OAS OPRC OIIP OVIP OREP OPDC OEXC OSCE OFFICIALS OMIG ODIP OFDP OECD OPIC OBSP OPCW OFDA OTR OSAC OSCI ON OCII OES OVP OIC OPAD OIE OHUM OCS
PREL PGOV PK PHUM PINS PARM PA PTER PINR PREF PHSA PBTS PBIO PO POL PE PARMS PM PROG PL PAK POLITICS PORG PTBS PNAT PUNE POLICY PDOV PCI PROP PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PBT PP PS PAO PG PY PTERE PGOF PALESTINIAN PKFK PSOE PEPR PPA PINT PMAR PRELP PSEPC PREFA PGOVE PINF PHUMPGOV PNG PMIL PGOC PFOR PCUL PLN PSA PGIV POLINT PAS POGOV PHUMPREL PHUMBA PEL PGGV PNR PHALANAGE PARTY PGOVLO PRAM PHUS PDEM PECON PF POV PROV PRL PREO PAHO PHUH PSI PINL PU PRGOV PAIGH POLITICAL PARTIES POSTS
QA
RS RU REACTION REPORT REGION RIGHTS RO RW RCMP RF RM RFE RSP RP RICE ROBERT ROOD RELATIONS RIGHTSPOLMIL RUPREL RSO
SU SNAR SO SOCI SW SENV SMIG SCUL SP SZ SENVKGHG SR SY SA SYRIA SF SI SC SWE SARS STEINBERG SN SG SIPRS ST SEVN SL SPCE SNARIZ SSA SNARCS SYR SK SPCVIS SHUM SIPDIS SHI SH SOFA SEN SNARN SAARC SAN SANC SCRS
TRGY TBIO TU TF TERRORISM TI TSPL TPHY TH TIP TSPA TC TO TW TX TZ TNGD TT TL TV TFIN TS TRSY TINT TN TURKEY TBID TD TK TR THPY TP TAGS
UNGA UN UK US UNC UNSC USUN UG UP UY USEU UNESCO USPS USTR UZ UNHRC UNO UNMIK UNAUS UNHCR UNCHR USAID UNVIE UAE USOAS UNFICYP UV UNEP UNODC UNCHS UNIDROIT UNDESCO UNDC UNCHC UNDP UNCND USNC UNPUOS UNICEF UNCSD UE
VT VE VTPREL VM VZ VI VTIZ VAT VN VC VTEG
WS WTO WTRO WTRQ WI WZ WHO WFP WBG WITH WWARD WHA WB WIPO WA WMO WMD WHTI WEU
XA XF XM XL XW XV XR XB XU XY XH XG XE XK XX XD XI XS XT XTAG XQ XZ XC
YE YM YI YMCS
ZI ZO ZU ZEALAND ZK ZR ZF ZP ZN ZA ZB ZOELLICK ZL ZJ ZANU

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06OTTAWA2021, POTENTIAL FOR IPR PROGRESS: CANADA'S PROPOSED

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06OTTAWA2021.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06OTTAWA2021 | 2006-06-29 19:07 | 2011-04-28 00:12 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Ottawa

`

    VZCZCXRO5122
    RR RUEHGA RUEHHA RUEHQU RUEHVC
    DE RUEHOT #2021/01 1801957
    ZNR UUUUU ZZH
    R 291957Z JUN 06
    FM AMEMBASSY OTTAWA
    TO RUEHC/SECSTATE WASHDC 3024
    INFO RUCNCAN/ALL CANADIAN POSTS COLLECTIVE
    RUCPDOC/DEPT OF COMMERCE WASHDC

` `

    UNCLAS SECTION 01 OF 02 OTTAWA 002021

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS TO USTR FOR GARDE, ESPINEL, CHANDLER
    STATE PASS TO USDOC FOR GWORD, JBOGER
    STATE PASS TO USPTO FOR MKEPLINGER

    E.O. 12958: N/A
    TAGS: KIPR ECON TBIO CA
    SUBJECT: POTENTIAL FOR IPR PROGRESS:  CANADA'S PROPOSED
    DATA PROTECTION REGULATIONS

    REF: A. OTTAWA 1701

         ¶B. OTTAWA 1317

    ¶1.  (SBU)  Summary:  The GOC has proposed a two-regulation
    package (significantly different from its 2004 proposal)
    consisting of data protection for the innovative
    pharmaceutical industries and "Patented Medicines (Notice of
    Compliance)" for the generic drug industries, a combination
    designed to force compromise between the two sectors.
    Although the innovative pharmaceutical industry organizations
    PhRMA and Rx&D have minor complaints which they hope to have
    addressed in the final regulations (the comment period ends
    July 17), in general the package seems to be a positive
    development for IPR protection in Canada.  In particular, the
    Data Protection regulation is designed to bring Canada into
    compliance with its international obligations to provide
    protection for proprietary data belonging to patent-holding
    companies, something that the Embassy has been encouraging.
    Assuming the proposed rules are finalized, industry observes
    believe that this will be a step forward for Canada's
    protection of IPR and will directly address one complaint
    from the last two Special 301 Reports on Canada.  End Summary.

    The Regulations
    ---------------

    ¶2.  (U)  (SBU)  The Patented Medicines (Notice of Compliance)
    or PMNOC regulation and, to a lesser extent, the Data
    Protection regulation are complex, and we would welcome
    insights from USG experts.  The data protection regulation
    can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle4-e.html
    The PMNOC regulation can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle6-e.html
    Our initial perusal and conversations with contacts have
    provided the following information.

    ¶3.  (SBU) The draft Data Protection regulation stipulates
    that a secondary manufacturer (usually a generic) cannot file
    a new drug submission on the basis of a direct or indirect
    comparison between the new drug and an innovative drug until
    six years after the first notice of compliance was issued to
    the innovator.  The submission will not be approved until at
    least eight years after the first notice of compliance was
    issued.  This data protection period of eight years compares
    favorably to the U.S. "five plus three" period.  (Comment:
    One observer joked to us that now Canada would have better
    data protection than the United States and that the
    innovative industry may start to use this as leverage to
    argue for better data protection in the United States.  End
    comment.)  Both the Canadian industry group Rx&D and PhRMA in
    the United States are preparing comments to submit to Health
    Canada.  From discussions with industry contacts, we believe
    the industry comments will focus on requests for
    clarification, particularly surrounding the transitional
    language that will determine how drug submissions already in
    the pipeline are treated.  A particular point which seems
    unclear to many observers (and of concern to the
    pharmaceutical industry) is paragraph (5) which states that
    the eight year protection period does not apply "if the
    innovative drug is not being marketed in Canada."  We expect
    that the final regulations will clarify how this will be
    applied.  However, the innovative industry's reaction to the
    data protection regulation is positive, with observers
    stating that this will not only bring Canada into compliance
    with its international obligations but will also make the
    country more competitive internationally.
    Qcountry more competitive internationally.

    ¶4.  (SBU)  The Patented Medicines (Notice of Compliance) or
    PMNOC regulation is the part of the package designed to keep
    the generic companies in the deal.  The PMNOC regulation is
    more complex than the data protection regulation, but in
    general it is intended to limit innovative drug companies'
    ability to "evergreen" drug patents, or renew patents based
    on small changes to a drug.  The PMNOC regulation attempts to
    address the unintended consequences of unclear language in
    previous regulation which required court interpretation;
    these include the "possibility that an innovator company may
    delay generic market entry by listing new and sometimes
    irrelevant patents on the basis of minor product revisions."
    In what seems to be a valuable victory for the innovative
    drug industry, however, the PMNOC's Regulatory Impact
    Assessment Statement states that dosage form patents (patents
    that focus on the form of the drug, not its chemical
    composition) deserve "special protection provided by the
    PM(NOC) regulations," adding that this is "particularly true

    OTTAWA 00002021  002 OF 002

    in the case of biologic drugs where effective administration
    of the medicinal ingredient is often dependent on the
    development of new and innovative delivery mechanisms."  The
    generic industry in Canada has not made any public statement
    on the draft regulations, although they will probably submit
    formal comments.  Our contacts also tell us that the generics
    are trying to arrange for meetings with relevant officials
    and members of parliament before the comment period ends on
    July 17.

    GOC Officials' Perspective
    ---------------------------

    ¶5.  (SBU) Our GOC contacts seem confident that these
    regulations will be finalized, with very few changes, in as
    short a period as is possible under Canada's regulatory
    process.  They describe the regulations as fair and balanced,
    and they suggest that neither the innovative nor the generic
    industry should be surprised by the regulations' content.  In
    general, this is what we are hearing from industry contacts
    as well, although industry contacts hesitate to describe
    themselves as happy with the regulations and insist that
    certain changes need to be made.  Any rhetoric about pushing
    for 10 years of data protection such as in Europe seems to be
    more a bargaining tool than an actual goal.  GOC officials
    are aware that both industries, but particularly the
    innovative industry, are eager for a package to be finalized
    and are willing to accept the compromises inherent in these
    proposed regulations.

    Domestic Political Context
    --------------------------

    ¶6.  (SBU) The current Conservative government has been more
    receptive to U.S. concerns about intellectual property
    rights, and domestically the Conservative party is less
    beholden to the generic industry, which is predominantly
    based in the greater Toronto area, a Liberal stronghold.
    (Comment:  a recent bit of much-hyped campaign scandal
    involved questionable donations to a Toronto-area Liberal
    MP--totalling C$54,000--from Apotex Inc's top two executives,
    their wives and six children.  Apotex is Canada's largest
    generic drug company.  End comment.)  The innovative drug
    companies, on the other hand, are primarily based in Quebec,
    where the Conservatives are very interested in picking up
    additional seats.  In general, this suggests that the
    generics industry, which is thought to be responsible for
    delaying progress on the 2004 proposal of the first version
    of these regulations, will not be able to delay progress on
    the new draft regulations.  The most optimistic timeframe for
    final regulations is probably the end of 2006.  As with our
    other IPR goal of amendments to the copyright act, much will
    hinge on whether another election is called in the meantime.
    An election before finalization of the regulations would at
    the very least delay them regulations and could result in yet
    another redraft.

    Visit Canada's Classified Web Site at
    http://www.state.sgov.gov/p/wha/ottawa

    WILKINS

`